Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Hum Mol Genet ; 25(7): 1357-69, 2016 Apr 01.
Article in English | MEDLINE | ID: mdl-26908621

ABSTRACT

Muscular dystrophy is characterized by progressive skeletal muscle weakness and dystrophic muscle exhibits degeneration and regeneration of muscle cells, inflammation and fibrosis. Skeletal muscle fibrosis is an excessive deposition of components of the extracellular matrix including an accumulation of Collagen VI. We hypothesized that a reduction of Collagen VI in a muscular dystrophy model that presents with fibrosis would result in reduced muscle pathology and improved muscle function. To test this hypothesis, we crossed γ-sarcoglycan-null mice, a model of limb-girdle muscular dystrophy type 2C, with a Col6a2-deficient mouse model. We found that the resulting γ-sarcoglycan-null/Col6a2Δex5 mice indeed exhibit reduced muscle pathology compared with γ-sarcoglycan-null mice. Specifically, fewer muscle fibers are degenerating, fiber size varies less, Evans blue dye uptake is reduced and serum creatine kinase levels are lower. Surprisingly, in spite of this reduction in muscle pathology, muscle function is not significantly improved. In fact, grip strength and maximum isometric tetanic force are even lower in γ-sarcoglycan-null/Col6a2Δex5 mice than in γ-sarcoglycan-null mice. In conclusion, our results reveal that Collagen VI-mediated fibrosis contributes to skeletal muscle pathology in γ-sarcoglycan-null mice. Importantly, however, our data also demonstrate that a reduction in skeletal muscle pathology does not necessarily lead to an improvement of skeletal muscle function, and this should be considered in future translational studies.


Subject(s)
Collagen Type VI/metabolism , Down-Regulation , Muscle, Skeletal/metabolism , Muscular Dystrophy, Animal/metabolism , Sarcoglycanopathies/metabolism , Animals , Mice , Mice, Knockout , Muscular Dystrophy, Animal/pathology , Muscular Dystrophy, Animal/physiopathology , Sarcoglycanopathies/pathology , Sarcoglycanopathies/physiopathology
2.
Hum Mutat ; 36(12): 1159-63, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26310427

ABSTRACT

Mutations in GDP-mannose pyrophosphorylase B (GMPPB), a catalyst for the formation of the sugar donor GDP-mannose, were recently identified as a cause of muscular dystrophy resulting from abnormal glycosylation of α-dystroglycan. In this series, we report nine unrelated individuals with GMPPB-associated dystroglycanopathy. The most mildly affected subject has normal strength at 25 years, whereas three severely affected children presented in infancy with intellectual disability and epilepsy. Muscle biopsies of all subjects are dystrophic with abnormal immunostaining for glycosylated α-dystroglycan. This cohort, together with previously published cases, allows preliminary genotype-phenotype correlations to be made for the emerging GMPPB common variants c.79G>C (p.D27H) and c.860G>A (p.R287Q). We observe that c.79G>C (p.D27H) is associated with a mild limb-girdle muscular dystrophy phenotype, whereas c.860G>A (p.R287Q) is associated with a relatively severe congenital muscular dystrophy typically involving brain development. Sixty-six percent of GMPPB families to date have one of these common variants.


Subject(s)
Dystroglycans/metabolism , Muscular Dystrophies/genetics , Muscular Dystrophies/metabolism , Mutation , Nucleotidyltransferases/genetics , Phenotype , Adolescent , Alleles , Biopsy , Brain/pathology , Child , Child, Preschool , Female , Genetic Association Studies , Heterozygote , Humans , Infant , Magnetic Resonance Imaging , Male , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Muscular Dystrophies/diagnosis , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...